Oral drugs for erectile dysfunction: Type 5 phosphodiesterase inhibits.
The evolution and availability of type 5 phosphodiesterase inhibitors have revolutionized the treatment of erectile dysfunction. The mechanism of their action is as follows: During sexual arousal, nitrate oxide (NO) is released from the neural structures of the oval body. Activates the enzyme guanylate cyclase, which leads to an increase in the content of genocide acid contained in the cells of the ovary. The result is a decrease in free calcium content in smooth muscle cells, relaxation, a sharp increase in blood flow, and cell proliferation of cavernosa corporations. By inhibiting phosphodiesterase-5, which is involved in the breakdown of gonadotropins, these drugs contribute to the development and maintenance of an erection during s*xual activity.